Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 26, 2023; 11(27): 6398-6406
Published online Sep 26, 2023. doi: 10.12998/wjcc.v11.i27.6398
Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
Hee Jun Choi, Jun Ho Lee, Chang Shin Jung, Jai Min Ryu, Byung Joo Chae, Se Kyung Lee, Jong Han Yu, Seok Won Kim, Seok Jin Nam, Jeong Eon Lee, Youn Joo Jung, Hyun Yul Kim
Hee Jun Choi, Jun Ho Lee, Chang Shin Jung, Department of Surgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon 51353, South Korea
Jai Min Ryu, Byung Joo Chae, Se Kyung Lee, Jong Han Yu, Seok Won Kim, Seok Jin Nam, Jeong Eon Lee, Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, South Korea
Youn Joo Jung, Hyun Yul Kim, Department of Surgery, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Gyeongnam 50612, South Korea
Author contributions: Choi HJ is the first author, planed and wrote this manuscript; all played a role in the data organization and modulation of this article; Kim HY planed, revised, edited and submitted this article.
Institutional review board statement: This study was approved by the Institutional Review Board of the Samsung Medical Center, Seoul, Korea (IRB file No. 2017-12-118-002). To protect personal information, patient records and information were anonymized and identities were removed prior to analysis.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: Dataset available from the corresponding author at isepa102@naver.com.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hyun Yul Kim, MD, PhD, Associate Professor, Department of Surgery, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Beomeo-ri, Mulgeum-eup, Yangsan-si, Gyeongnam 50612, South Korea. isepa102@naver.com
Received: June 23, 2023
Peer-review started: June 23, 2023
First decision: July 4, 2023
Revised: July 17, 2023
Accepted: August 25, 2023
Article in press: August 25, 2023
Published online: September 26, 2023
Processing time: 88 Days and 19.6 Hours
Core Tip

Core Tip: The treatment of ovarian suppression was effected a better oncology outcome in the group with clinical high risk, hormone receptor (+) breast cancer. However few studies have compared the efficacy of gonadotropin-releasing hormone (GnRH) agonists for 2 years in patients with neoadjuvant chemotherapy. The aim of our study was to evaluate the efficacy of GnRH agonist treatment in young breast cancer patients.